TCGA-D8-A145-01A-11R-A115-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 14
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.410
- TGF_BETA_SIGNALING+0.350
- WNT_BETA_CATENIN_SIGNALING+0.330
- HEDGEHOG_SIGNALING+0.250
- ANDROGEN_RESPONSE+0.160
- APICAL_JUNCTION+0.160
- NOTCH_SIGNALING+0.150
- APICAL_SURFACE+0.090
- KRAS_SIGNALING_UP+0.090
- HEME_METABOLISM+0.070
Top 10 suppressed
- E2F_TARGETS-0.550
- INTERFERON_ALPHA_RESPONSE-0.550
- OXIDATIVE_PHOSPHORYLATION-0.530
- MYC_TARGETS_V1-0.510
- MTORC1_SIGNALING-0.430
- G2M_CHECKPOINT-0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.390
- INTERFERON_GAMMA_RESPONSE-0.370
- MYC_TARGETS_V2-0.370
- CHOLESTEROL_HOMEOSTASIS-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0E9-01B-11R-A115-07 | — | A | 0.889 |
| 2 | TCGA-AR-A2LM-01A-11R-A180-07 | — | A | 0.880 |
| 3 | SRR29022838 | — | A | 0.880 |
| 4 | MBCProject_0719_T3_RNA | — | A | 0.877 |
| 5 | TCGA-D8-A4Z1-01A-21R-A266-07 | — | A | 0.873 |
| 6 | ULC0424T_S49 | — | cohortA1 | 0.869 |
| 7 | SRR8613781 | — | A | 0.860 |
| 8 | TCGA-BH-A0DO-01B-11R-A12D-07 | — | A | 0.859 |
| 9 | TCGA-D8-A27K-01A-11R-A16F-07 | — | A | 0.857 |
| 10 | SRR8613708 | — | A | 0.855 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.410 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.330 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.160 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.150 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.090 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.090 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.070 | Inavolisib | — uncovered |
| MYOGENESIS | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.010 | Inavolisib | — uncovered |